Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92f29afac6c4db812a65d42e5a46b7fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
filingDate |
2014-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b580700bb88370f42a66a47961d7bdc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3f24a3d1fb62260f4dbf75fd5f2e2e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a137d95f0aca8959fd8c28aa03017ece http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d3062d9ff8e7ea6e97261fdef23cd3 |
publicationDate |
2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2017007685-A1 |
titleOfInvention |
TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES |
abstract |
A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018218151-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11684637-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018273963-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110891584-A |
priorityDate |
2013-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |